The present invention relates to a novel naphtho class of compounds as Stat3 pathway inhibitors and as cancer stem cell inhibitors; to methods of using such compounds to treat cancer; to methods of using such compounds to treat disorders in a mammal related to aberrent Stat3 pathway activity; to pharmaceutical compositions containing such compounds.

The present invention relates to a novel naphtho class of compounds as Stat3 pathway inhibitors and as cancer stem cell inhibitors; to methods of using such compounds to treat cancer; to methods of using such compounds to treat disorders in a mammal related to aberrent Stat3 pathway activity; to pharmaceutical compositions containing such compounds.

The present invention provides compounds of formulae (1) (2) wherein R.sup.1 and R.sup.2 are C.sub.1-30alkyl, C.sub.2-3O-alkenyl, C.sub.2-30-alkynyl, C.sub.5-7-cycloalkyl, C.sub.6-14-aryl or 5 to 14 membered heteroaryl, wherein C.sub.1-30-alkyl, C.sub.2-3O-alkenyl and C.sub.2-3O-alkynyl can be substituted with one or more substituents selected from the group consisting of halogen, phenyl, OC.sub.1-20-alkyl, OC.sub.2-20-alkenyl and OC.sub.2-2O-alkynyl, and wherein C.sub.5-7-cycloalkyl, C.sub.6-14-aryl and 5 to 14 membered heteroaryl can be substituted with one or more substituents selected from the group consisting of halogen, C.sub.1-20alkyl, C.sub.2-2O-alkenyl, C.sub.2-2O-alkynyl, OC.sub.1-20-alkyl, OC.sub.2-2o-alkenyl and OC.sub.2-2o-alkynyl, R.sup.a, R.sup.b, R.sup.c and R.sup.d are independently and at each occurrence selected from the group consisting of C.sub.1-30alkyl, C.sub.2-30-alkenyl, C.sub.2-30-alkynyl, C.sub.6-14-aryl and 5 to 14 membered heteroaryl, wherein C.sub.1-30-alkyl, C.sub.2-3o-alkenyl and C.sub.2-3o-alkynyl can be substituted with one or more substituents selected from the group consisting of halogen, phenyl, OC.sub.1-20-alkyl, OC.sub.2-20-alkenyl and OC.sub.2-20-alkynyl, and wherein C.sub.5-7-cycloalkyl, C.sub.6-14-aryl and 5 to 14 membered heteroaryl can be substituted with one or more substituents selected from the group consisting of halogen, C.sub.1-20alkyl, C.sub.2-2o-alkenyl, C.sub.2-20-alkynyl, OC.sub.1-20-alkyl, OC.sub.2-20-alkenyl and OC.sub.2-2o-alkynyl, n and o are independently 0, 1, 2, 3, 4 or 5, and m and p are independently 0, 1, 2 or 3, and to electronic device comprising the compounds of formulae 1 or 2.

##STR00001##

Disclosed are compounds of Formula (I), Formula (II), Formula (III), and Formula (IV) or salts thereof, wherein R.sub.2 is OH or OP(O)(OH).sub.2; and R.sub.1 is defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein coupled receptor S1P.sub.1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease. ##STR00001##

Disclosed are compounds of Formula (I), Formula (II), Formula (III), and Formula (IV) or salts thereof, wherein R.sub.2 is OH or OP(O)(OH).sub.2; and R.sub.1 is defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein coupled receptor S1P.sub.1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease. ##STR00001##

A method of synthesizing a fused heteroaromatic compound includes obtaining a first intermediate from a first compound represented by Chemical Formula 1 and a second compound represented by Chemical Formula 2, obtaining a second intermediate including a ring having a chalcogen element from the first intermediate, and obtaining a fused heteroaromatic compound by a cyclization reaction of the second intermediate.

A method of synthesizing a fused heteroaromatic compound includes obtaining a first intermediate from a first compound represented by Chemical Formula 1 and a second compound represented by Chemical Formula 2, obtaining a second intermediate including a ring having a chalcogen element from the first intermediate, and obtaining a fused heteroaromatic compound by a cyclization reaction of the second intermediate.

The present invention relates to the use of a novel class of cancer stem cell pathway (CSCP) inhibitors; to methods of using such compounds to treat refractory, recurrent, or metastatic cancers; to methods of selective killing cancer cells by using such compounds with specific administration regimen; to methods of targeting cancer stem cells by inhibiting Stat3 pathway; to methods of using novel compounds in the treatment of conditions or disorders in a mammal related to aberrant Stat3 pathway activity; and to processes for preparing such compounds and intermediates thereof, and to the pharmaceutical compositions of relevant compounds, and to the specific methods of administration of these compounds.

The present invention relates to the use of a novel class of cancer stem cell pathway (CSCP) inhibitors; to methods of using such compounds to treat refractory, recurrent, or metastatic cancers; to methods of selective killing cancer cells by using such compounds with specific administration regimen; to methods of targeting cancer stem cells by inhibiting Stat3 pathway; to methods of using novel compounds in the treatment of conditions or disorders in a mammal related to aberrant Stat3 pathway activity; and to processes for preparing such compounds and intermediates thereof, and to the pharmaceutical compositions of relevant compounds, and to the specific methods of administration of these compounds.

A highly heat-resistant organic compound with favorable hole-transport properties is provided. The organic compound is represented by General Formula (G1). In General Formula (G1), X represents a sulfur atom or an oxygen atom, and R.sup.21 to R.sup.25 and R.sup.27 to R.sup.30 each independently represent any one of hydrogen, halogen, a nitrile group, an alkenyl group, a vinyl group, an alkynyl group, an ethynyl group, a straight-chain alkyl group having 1 to 6 carbon atoms, a cycloalkyl group having 3 to 10 carbon atoms, an alkoxy group having 1 to 6 carbon atoms, an alkylsilyl group having 3 to 10 carbon atoms, an aryl group having 6 to 30 carbon atoms, and a heteroaryl group having 2 to 30 carbon atoms. Ar.sup.1 represents an aryl group having 6 to 30 carbon atoms or a heteroaryl group having 2 to 30 carbon atoms. Ar.sup.2 is represented by General Formula (G1-1).

##STR00001##